Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-21
2006-11-21
Duffy, Patricia A. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S387900, C530S388150, C530S391100, C530S391300, C530S391700
Reexamination Certificate
active
07138501
ABSTRACT:
The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.
REFERENCES:
patent: 6297367 (2001-10-01), Tribouley
patent: 6403770 (2002-06-01), Yu et al.
patent: 6562579 (2003-05-01), Yu et al.
patent: 2001/0010925 (2001-08-01), Wiley
patent: 2002/0055624 (2002-05-01), WIley
patent: 2003/0012783 (2003-01-01), Kindsvogel
patent: 0869180 (1998-10-01), None
patent: 0921194 (1999-06-01), None
patent: WO97/33902 (1997-09-01), None
patent: WO98/18921 (1998-05-01), None
patent: WO98/27114 (1998-06-01), None
patent: WO98/55620 (1998-12-01), None
patent: WO98/55621 (1998-12-01), None
patent: WO99/11791 (1999-03-01), None
patent: WO99/12964 (1999-03-01), None
patent: WO99/33980 (1999-07-01), None
patent: WO00/26244 (2000-05-01), None
patent: WO00/39295 (2000-07-01), None
patent: WO00/40716 (2000-07-01), None
patent: WO00/43032 (2000-07-01), None
patent: WO00/45836 (2000-08-01), None
patent: WO00/47740 (2000-08-01), None
patent: WO00/50597 (2000-08-01), None
patent: WO00/60079 (2000-10-01), None
patent: WO00/67034 (2000-11-01), None
patent: WO00/68378 (2000-11-01), None
patent: WO00/77256 (2000-12-01), None
patent: WO01/40466 (2001-06-01), None
patent: WO01/87977 (2001-11-01), None
Kennell, D.E., Prog. Nucl. Acid Res. Med. Biol, 11:259-301 1971.
Kabat et al Sequences of Proteins of Immunological Interest Forth Edition, 1987, pp. 44, 53, 54, 63, 69, 70, and 76.
Ashkenazi, et al., Response, Nature Immunology, (2000) 1:179.
Baumgarth, Nicole, Secreted IgM versus BLyS in Germinal Center Formation, Nature Immunology, (2000) 1:179.
Batten et al., BFF Mediates Survival of Peripheral Immature B Lymphocytes. The Journal of Experimental Medicine, (2000) 192:1453-65.
Cheema et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, Arthritis and Rheumatism (2001) 44:1313-1319.
Cyster, Jason G., B Cells on the Front Line, Nature Immunology, (2000) 1:9-10.
Do et al., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response, The Journal of Experimental Medicine, (2000) 192: 953-964.
Dorner and Putterman, B cells, BAFF/zTNF4, TACI, and Systemic Lupus Erythematosus, Arthritis Research (2001) 3:197-9.
Gross et al., TACI and BCMA are receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease, Nature, (2000) 404:995-999.
Hatzoglou et al., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF-kB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, The Journal of Immunology, (2000) 165:1322-1330.
Hu et al., Characterization of TNFRSF19, a Novel Member of the Tumor Necrosis Factor Receptor Superfamily, Genomics, 62:1023-107 (1999).
Khare et al., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, The Proceedings of the National Academy of Sciences, (2000) 97:3370-3375.
Laabi et al., Lymphocyte Survival-Ignorance is BLyS, Science, (2001) 289-883.
Mackay et al., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, The Journal of Experimental Medicine, (1999) 190:1697-1710.
Marsters, et al., Interaction of the TNF Homologues BLyS and APRIL. with the TNF Receptor Homologues BCMA and TACI Current Biology, (2000) 10:785-788.
Moore et al., BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, (1999) 285:260-263.
Mukhopadhay et al., Identification and Characterization of a Novel Cytokine, THANK, A TNF Homologue That Activates Apoptosis, Nuclear Factor-KB, c-Jun NH2 Terminal Kinase (1999) The Journal of Biological Chemistry 274:15978-81.
Nardelli et al., Synthesis and Release of B-Iymphocyte Stimulator from Myeloid Cells, Blood, (2001) 97:198-204.
Parry et al., Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BLyS) in Mice, The Journal of Pharmacology and Experimental Therapeutics, (2001) 296:396-404.
Schneider et al., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, The Journal of Experimental Medicine, (1999) 189:1747-1756.
Shu et al., TALL-1 is a Novel Memeber of the TNF Family that is Down-Regulated by Mitogens, Journal of Leukocyte Biology, (1999) 65:680-683.
Thompson et al., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, The Journal of Experimental Medicine, (2000) 192:129-135.
Tribouley et al, Characterization of a New Member of the TNF Family Expressed on Antigen Presenting Cells, (1999) Biological Chemistry 380:1443-7.
Ware, Carl, APRIL and BAFF Connect Autoimmunity and Cancer. The Journal of Experimental Medicine (2000) 192:F35-F37.
Xia et al., TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, The Journal of Experimental Medicine, (2000) 192:137-143.
Yan et al., Identification of a receptor for BLyS Demonstrates a Crucial Role in Humoral Immunity, Nature Immunology, (2000) 1:37-41.
Yu et al., APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity, Nature Immunology, (2000) 1:252-256.
Zhang et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, The Journal of Immunology, (2001) 166:6-10.
Kanakaraj et al., BLyS Binds to B Cells With High Affinity and Induces Activation of the Transcription Factors NF-kB and Elf-1, Cytokine (2001) 13:25-31.
Wu et al., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BLyS, The Journal of Biological Chemistry (2000) 275:35478-35485.
Choi Gil H.
Hilbert David
Ruben Steven M.
Vaughan Tristan
Duffy Patricia A.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
LandOfFree
Antibodies that immunospecifically bind BLyS does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that immunospecifically bind BLyS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that immunospecifically bind BLyS will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3641833